USP Announces Corrections to General Chapter <1132.1> on Residual Host Cell Protein Measurement
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
The United States Pharmacopeia (USP) has announced minor corrections to General Chapter <1132.1> Residual Host Cell Protein Measurement in Biopharmaceuticals by Mass Spectrometry. The chapter was originally published in Pharmacopeial Forum 49(3) and subsequently approved for publication on 01 November 2024, in USP-NF 2025, Issue 1.
The following errata were published on 31 January 2025, and all changes will take effect on 01 May 2025:
- Section 1. INTRODUCTION AND SCOPE – In paragraph 3: Change Residual HCP ELISA to: HCP ELISA.
- Section 4. SAMPLE PREPARATION, CHROMATOGRAPHIC SEPARATION, AND MASS SPECTROMETRY ANALYSIS – In paragraph 4 in 4.1 Sample Preparation: Change product (or polysorbate) to: product protein (or polysorbate).
- Section 5. QUANTITATION OF HCPS – In three instances in 5.1 Methods for HCP Quantitation: Change product to: product protein.
- Section 7. BEST PRACTICES FOR REPORTING DATA FROM ELISA VERSUS LC-MS/MS – In paragraph 1 in 7.3 Comparison of ELISA and LC-MS/MS HCP Results: Change the comparing to: comparing.
For a comprehensive list of errata, refer to the USP-NF Errata Table.
Additionally, please see the Notice of Intent to Revise, published on 01 November 2024, for further details.
Related GMP News
15.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
15.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity
10.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
26.11.2025FDA Warning Letter Highlights Deficiencies in SST and HPLC Practices
13.11.2025Proposed Revision of USP <1225> Published in the Pharmacopeial Forum


